Literature DB >> 21926377

N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.

Yoshiharu Ohno1, Hisanobu Koyama, Takeshi Yoshikawa, Mizuho Nishio, Nobukazu Aoyama, Yumiko Onishi, Daisuke Takenaka, Sumiaki Matsumoto, Yoshimasa Maniwa, Wataru Nishio, Yoshihiro Nishimura, Tomoo Itoh, Kazuro Sugimura.   

Abstract

PURPOSE: To prospectively compare the diagnostic capability of short inversion time inversion-recovery (STIR) turbo spin-echo (SE) imaging, diffusion-weighted (DW) magnetic resonance (MR) imaging, and fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in N stage assessment in patients with non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: This prospective study was approved by the institutional review board, and written informed consent was obtained from all patients. A total of 250 consecutive patients with NSCLC (136 men; mean age, 73 years; 114 women; mean age, 72 years) prospectively underwent pretherapeutic STIR turbo SE imaging, DW MR imaging, and FDG PET/CT, as well as surgical and pathologic examinations (N0 disease, n = 157; N1 disease, n = 72; N2 disease, n = 16; N3 disease, n = 5). Lymph node-to-saline ratio (LSR), lymph node-to-muscle ratio (LMR), apparent diffusion coefficient (ADC), maximal standardized uptake value (SUV(max)), and visual scoring were assessed for 135 metastatic lymph nodes and 135 randomly selected nonmetastatic lymph nodes. Receiver operating characteristic curve analysis was used to determine feasible threshold values. Diagnostic capabilities for N stage assessment were compared with the McNemar test on a per-patient basis.
RESULTS: When feasible, threshold values were used for quantitative assessment; sensitivity and accuracy of LSR and LMR (sensitivity, 82.8%; accuracy, 86.8%) proved to be significantly higher than those of ADC (sensitivity: 74.2%, P = .01; accuracy: 84.4%, P = .04) and SUV(max) (sensitivity: 74.2%, P = .01). For qualitative assessment, sensitivity of STIR turbo SE imaging (77.4%) was significantly higher than that of DW MR imaging (71.0%, P = .03) and FDG PET/CT (69.9%, P = .02).
CONCLUSION: Quantitative and qualitative assessments of N stage disease in patients with NSCLC obtained with STIR turbo SE MR imaging are more sensitive and/or more accurate than those obtained with DW MR imaging and FDG PET/CT. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11110281/-/DC1. RSNA, 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926377     DOI: 10.1148/radiol.11110281

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

1.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

2.  N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience.

Authors:  A A Kohan; J A Kolthammer; J L Vercher-Conejero; C Rubbert; S Partovi; R Jones; K A Herrmann; P Faulhaber
Journal:  Eur Radiol       Date:  2013-06-14       Impact factor: 5.315

3.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

4.  PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.

Authors:  Svetlana Balyasnikova; Johan Löfgren; Robin de Nijs; Yanna Zamogilnaya; Liselotte Højgaard; Barbara M Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis.

Authors:  Tomohiro Haruki; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-05-23       Impact factor: 1.520

6.  Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study.

Authors:  Sileny N Han; Frédéric Amant; Katrijn Michielsen; Frederik De Keyzer; Steffen Fieuws; Kristel Van Calsteren; Raphaëla C Dresen; Mina Mhallem Gziri; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

7.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Authors:  Katrijn Michielsen; Ignace Vergote; Katya Op de Beeck; Frederic Amant; Karin Leunen; Philippe Moerman; Christophe Deroose; Geert Souverijns; Steven Dymarkowski; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

8.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

Review 9.  PET and MR imaging: the odd couple or a match made in heaven?

Authors:  Ciprian Catana; Alexander R Guimaraes; Bruce R Rosen
Journal:  J Nucl Med       Date:  2013-03-14       Impact factor: 10.057

10.  Optimized 3D ultrashort echo time pulmonary MRI.

Authors:  Kevin M Johnson; Sean B Fain; Mark L Schiebler; Scott Nagle
Journal:  Magn Reson Med       Date:  2012-12-04       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.